BSJ-5-63 is an effective degrader of CDK12, CDK7, and CDK9. It reduces the protein expression of CDK12, CDK7, CDK9, RNAPII, and Cyclin K, and also decreases the mRNA expression of BRCA1 and BRCA2. BSJ-5-63 exhibits anticancer activity and holds potential for prostate cancer research.

BSJ-5-63, administered at concentrations ranging from 0-1000 nM for 8 hours, dose-dependently reduces the protein expression of CDK12, CDK7, CDK9, RNAPII, and Cyclin K. Additionally, at the same concentrations but over periods of 8, 16, and 24 hours, BSJ-5-63 exhibits both dose- and time-dependent decreases in the mRNA expression of BRCA1 and BRCA2.

BSJ-5-63, administered intraperitoneally at a dosage of 50 mg/kg daily over a span of 12 days, exhibited anticancer activity in a model using male ICR-SCID mice aged 4-5 weeks and implanted with 22Rv1 cells. This regimen not only significantly curtailed the growth and weight of the 22Rv1 tumors but also markedly increased apoptotic cell counts. Additionally, it resulted in an approximate 10% weight loss in the treated mice.